Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Relmacabtagene autoleucel - JW Therapeutics

Next Previous
Drug Profile

Relmacabtagene autoleucel - JW Therapeutics

Alternative Names: Carteyva; JWCAR-029; relma-cel

Latest Information Update: 28 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Juno Therapeutics
  • Developer JW Therapeutics; Shanghai Ming Ju Biotechnology
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Preregistration Diffuse large B cell lymphoma
  • Phase I Chronic lymphocytic leukaemia; Systemic lupus erythematosus
  • No development reported Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 28 May 2025 No recent reports of development identified for phase-I development in Precursor-B-cell-lymphoblastic-leukaemia-lymphoma(In adolescents, In children, Second-line therapy or greater, In adults) in China (IV)
  • 10 Jan 2025 Ming Ju Biotechnology initiates a phase II trial for Non-Hodgkin's lymphoma (Second line therapy or greater) in China (IV) (NCT06093841)
  • 10 Jan 2025 Relmacabtagene autoleucel - JW Therapeutics receives Breakthrough Therapy status for B-cell lymphoma (Second-line therapy or greater) in China

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top